The European Association for Cardio-Thoracic Surgery (EACTS) is holding their annual meeting from October 1-5 in Barcelona, Spain. T3 Labs was originally founded as a cardiovascular research institute, and boasts a decade long track-record in preclinical cardiovascular studies.
“The facilities [at T3 Labs] are top tier. They are designed to make it easy to move from concept through protocol to budgeting and now it happens as efficiently as possible.” -Dr. Robert Matheny, MD, Chief Scientific Officer of CorMatrix
The EU is one of the largest markets for medical devices. Regulatory bodies are structured to allow practitioners in the EU to use, deploy or implant devices a generation or two ahead of other markets, making them the first to clinically evaluate the success or failure of a new medical device. Oftentimes, initial adoption, effectiveness and safety have already been given the CE mark of approval long before a product is launched in the United States.
This year, Andrew Stevenson, Executive Director of Business Development, and Christopher Rolfes, Preclinical Testing Program Manager, will be representing T3 Labs at EACTS meeting with cardiothoracic industry leaders and keeping up with the with the latest in medtech for cardiac surgery, as well as current trends for the medical devices surgeons employ.
The value in attending EACTS for T3
The EACTS Annual Meeting is the premier European opportunity to keep up with state of the art advancements in Acquired Cardiac, Congenital Heart, Vascular and Thoracic Diseases. The conference will focus on developments across cardio-thoracic specialties, from basic science to clinical experience. Being in attendance grants us the opportunity to learn multiple aspects of cardiothoracic surgery, and also view live cases.
Sessions on the EACTS program that have our attention
The Annual Techno-College of EACTS 2016 sessions held on Saturday October 1st: The day will include forums and breakout sessions that focus on the technical aspects of congenital, thoracic, and vascular surgery.
The TAVR vs. SAVR focus session held on October 2nd: There is an ongoing debate to decide whether Transcatheter or Surgical Aortic-Valve Replacement is the appropriate route for patients with severe aortic stenosis. In this session we will hear both sides from industry leaders.
You can access the full EACTS 2016 program here.
If you specialize in developing cardiothoracic therapies, be they devices, drugs, combination devices, or if you just want to talk about the latest in cardiothoracic innovation, we want to connect with you!
Contact T3 Labs Executive Director D. Andrew Stevenson to arrange a meeting at EACTS 2016!